Tofacitinib citrate | 540737-29-9

Tofacitinib citrate Properties

Melting point	201 °C (decomp)
storage temp.	room temp
solubility	DMSO: soluble5mg/mL (clear solution; warmed)
form	powder
color	white to beige
InChIKey	SYIKUFDOYJFGBQ-YLAFAASESA-N
SMILES	C1[C@@H](C)[C@@H](N(C2C3=C(NC=C3)N=CN=2)C)CN(C(CC#N)=O)C1.C(C(=O)O)C(C(=O)O)(O)CC(O)=O \|&1:1,3,r\|
FDA UNII	O1FF4DIV0D

Pharmacokinetic data

Protein binding	40%
Excreted unchanged in urine	30%
Volume of distribution	87 Litres
Biological half-life	3 / 3.8

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H315-H319

Precautionary statements

P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

WGK Germany

3

HS Code

29335990

NFPA 704

	0
2		0

Tofacitinib citrate price More Price(39)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	PZ0017	Tofacitinib citrate ≥98% (HPLC)	540737-29-9	5mg	$127	2024-03-01	Buy
Sigma-Aldrich	PZ0017	Tofacitinib citrate ≥98% (HPLC)	540737-29-9	25mg	$505	2024-03-01	Buy
Cayman Chemical	11598	CP 690,550 ≥98%	540737-29-9	5mg	$68	2024-03-01	Buy
Cayman Chemical	11598	CP 690,550 ≥98%	540737-29-9	10mg	$130	2024-03-01	Buy
Cayman Chemical	25046	Tofacitinib-d3 (citrate) ≥99% deuterated forms (d₁-d₃)	540737-29-9	1mg	$668	2024-03-01	Buy

Product number	Packaging	Price	Buy
PZ0017	5mg	$127	Buy
PZ0017	25mg	$505	Buy
11598	5mg	$68	Buy
11598	10mg	$130	Buy
25046	1mg	$668	Buy

Tofacitinib citrate Chemical Properties,Uses,Production

Description

Tofacitinib citrate, also known as CP-690550 citrate, is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.

Uses

Tofacitinib citrate has been used:
as a ligand for human serum albumin in fluorescence quenching, dynamic light scattering (DLS) measurements, differential scanning calorimetry and molecular docking studies
as a medium supplement for full depth articular cartilage (FDC) explants to monitor cytokine-induced proteoglycan loss
as a Janus kinase inhibitor in MCF7 breast cancer cells

Definition

ChEBI: Tofacitinib citrate is a citrate salt obtained by combining equimolar amounts of tofacitinib and citric acid. Used to treat moderately to severely active Rheumatoid Arthritis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antirheumatic drug. It contains a tofacitinib.

General Description

Tofacitinib is a synthetic molecule corresponding to a molecular weight of 312.4 Da and is permeable by transcellular diffusion.

Biological Activity

tofacitinib citrate, also known as cp-690550 citrate, is a potent inhibitor of janus kinase 3 (jak3), a hematopoetic cell-restricted tyrosine kinase involved in signal transduction regulating lymphocyte survival, proliferation, differentiation, and apoptosis. the inhibition is jak3 specific with a selectivity 1000-fold more than other non-jak family kinases. besides inhibiting jaks (ic50 = 1 nm), tofacitinib citrate also inhibits janus kinase 2 (jak2) and janus kinase 1 (jak1) with 20- and 100-fold less in potency respectively. however, in a recent study, the binding affinities (ki) of tofacitinib citrate towards jak1, jak2, and jak3 were reported to be 1.6 nm, 21.7 nm, and 6.5 nm respectively.lalitha vijayakrishnan, r. venkataramanan and palak gulati. treating inflammation with the janus kinase inhibitor cp-690,550. trends in pharmacological sciences 2011: 32 (1); 25-34

Biochem/physiol Actions

Tofacitinib is a potent inhibitor of Janus kinase 3 (JAK3) with some JAK-1 inhibitory activity as well. It blocks downstream STAT signaling resulting in potent inhibition of inflammatory cytokines with resultant immunosuppressive and anti-inflammatory activity. Tofacitinib is being investigated for for several autoimmune disorders including, rheumatoid arthritis, psoriasis and dry eye.

Clinical Use

Potent, selective inhibitor of the Janus kinase family:
Treatment of moderate to severe active rheumatoid arthritis

in vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20-to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

in vivo

In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ～60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrate dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.).

target

JAK3

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: concentration of tofacitinib reduced by rifampicin - avoid.
Antifungals: concentration of tofacitinib increased by fluconazole and ketoconazole - adjust tofacitinib dose.
Antipsychotics: increased risk of agranulocytosis with clozapine - avoid.
Ciclosporin: concentration of tofacitinib reduced - avoid.
Tacrolimus: concentration of tofacitinib reduced - avoid.
Vaccines: risk of generalised infections with live vaccines - avoid.ccccccc

Metabolism

70% metabolised in the liver by CYP3A4 (major) and CYP2C19 (minor). The 8 metabolites produced are inactive.

References

1. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. PMID: 26966791
2. Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach DOI:10.1080/07391102.2015.1104522
3. Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo. DOI:10.1016/j.bcp.2018.07.034
4. Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer DOI:10.18632/oncotarget.21801
5. Lalitha Vijayakrishnan, R. Venkataramanan and Palak Gulati. Treating inflammation with the janus kinase inhibitor CP-690,550. Trends in Pharmacological Sciences 2011: 32 (1); 25-34 DOI:10.1016/j.tips.2010.10.004
6. http://www.medicinenet.com/tofacitinib_citrate_xeljanz/article.htm

Tofacitinib citrate Preparation Products And Raw materials

Raw materials

Preparation Products

Tofacitinib citrate Suppliers

Global( 610)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Senova Technology Co. Ltd.	+86-0755-86703119 +8618503098836	info@senovatech.com	China	349	58
AFINE CHEMICALS LIMITED	0571-85134551	info@afinechem.com	CHINA	15377	58
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.	+86-029-86185165 +8618629664246	guoyuan@eastchinapharm.com	China	1615	58
Changsha Junyu Chemexpress.co., Ltd	+86-13723890100	info@csjyyy.cn	China	134	58
Changzhou Rokechem Technology Co., Ltd.	18758118018	sales001@rokechem.com	China	255	58
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	+86-576-88902229;+86-0576-88902229 +8613968687450	yuxin@yuxchem.com	China	122	58
Zibo Wei Bin Import & Export Trade Co. Ltd.	+86-0533-2091136 +8613864437655	ziboweibinmaoyi@163.com	China	100	58
Hebei Duling International Trade Co. LTD	+8618032673083	sales05@hbduling.cn	China	15747	58
shandong perfect biotechnology co.ltd	+86-53169958659; +8618596095638	sales@sdperfect.com	China	294	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	7377	58

Supplier	Advantage
Senova Technology Co. Ltd.	58
AFINE CHEMICALS LIMITED	58
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.	58
Changsha Junyu Chemexpress.co., Ltd	58
Changzhou Rokechem Technology Co., Ltd.	58
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	58
Zibo Wei Bin Import & Export Trade Co. Ltd.	58
Hebei Duling International Trade Co. LTD	58
shandong perfect biotechnology co.ltd	58
Henan Fengda Chemical Co., Ltd	58

View Lastest Price from Tofacitinib citrate manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2024-04-13	Tofacitinib citrate 540737-29-9	US $0.00 / kg	1kg	99%	10000kg	Shaanxi TNJONE Pharmaceutical Co., Ltd
2024-04-10	Tofacitinib Citrate 540737-29-9	US $0.00 / Kg/Bag	2Kg/Bag	99% up	20tons	Sinoway Industrial co., ltd.
2024-04-07	Tofacitinib citrate 540737-29-9	US $100.00 / kg	1kg	99%	1t	Zibo Wei Bin Import & Export Trade Co. Ltd.

Tofacitinib citrate
540737-29-9
US $0.00 / kg
99%
Shaanxi TNJONE Pharmaceutical Co., Ltd

Tofacitinib Citrate
540737-29-9
US $0.00 / Kg/Bag
99% up
Sinoway Industrial co., ltd.

Tofacitinib citrate
540737-29-9
US $100.00 / kg
99%
Zibo Wei Bin Import & Export Trade Co. Ltd.

Tofacitinib citrate Spectrum

Tofacitinib citrate(540737-29-9)¹HNMR

540737-29-9(Tofacitinib citrate)Related Search:

Sildenafil Chlorosulfonyl N-Hydroxysuccinimide Tofacitinib Impurity 2 N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine

Tofacitinib Related Compound (3R,4R)-N,1,4-trimethyl-N-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidin-3-amine 3-Piperidinamine,4-methyl-1-(phenylmethyl)-,(3R,4R)-rel- methyl3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin -4-yl)amino)piperidin-1-yl)-3-oxopropanoate Azathioprine

3-bis(4-Methylbenzoyloxy)succinate) N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine dihydrochloride (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride Vorinostat Dabrafenib

Sunitinib Malate Crizotinib PLX4032

1of4

1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) CP-690550 (Tofacitinib citrate) CP 690500-10 CP 690550-10 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-, citrate 1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE Tofacitinib citrate, >=98% 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Tofacitinib citrate (CP-690550) Tofacitinib citrate Tasocitinib citrate Tasocitinib citric acid s... 3-PiperidinaMine, 1-(cyanoacetyl)-4-Methyl-N-Methyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) 3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Tofacitinib, Citrate Salt, >99% 3-{(3R,4R )-4-Methyl-3-[methyl(7H –pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile monocitrate Tasocitinib citric acid salt 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile citrate CP-690550 citrate Tofacitinib Citratet 3-{4-Methyl-3-[Methyl-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-aMino]-piperidin-1-yl}-3-oxo-propionitrile Tofacitinib API Tofacitinib citric acid salt (3r,4r)-4-Methyl-3-(Methyl-7h-pyrrolo(2,3-d)pyriMidin-4-ylaMino)-beta-oxo-1 Tofacititinib cirate CP-690550 Citrate (Tofacitinib Citrate) Tofacitinib (Tasocitinib, CP-690550) (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate Tofacitinib citrate(CP690550) Tofacitinib citrate (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-bet (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile citrate salt 3-[(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt Tasocitinib citrate salt Xeljanz(tofacitinib) Citrate Tropsch iMatinib 1-Piperidinepropanenitrile,4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-,(3R,4R)-,2-hydroxy-1,2,3-propanetricarboxylate 3-[(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidyl]-3-oxopropanenitrile 2-Hydroxypropane-1,2,3-tricarboxylate Tofacitinib citrate - CP 690550-10 Tofacitinib-13C-d3 Citrate CS-656 Tofacitinib citrate (CP-690553 citrate) ofacitinibcitrate 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, citrate (1:1) Tofacitinib citrate ISO 9001：2015 REACH CP-690550 Citrate (Tofacitinib Citrate) DISCONTINUED tofacitinib citratoTofacitinib citrate Tofacitinib Citrate (API) (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,... tofacitinib citrate1004 tofacitinib citrate1005 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate (Tofacitinib Impurity) 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Tofacitinib citrate (540737-29-9) Tofacitinib citrate (CP-690550 citrate) (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile citrate CP-690550; TOFACITINIB; TASOCITINIB Xeljanz